UPDATE:! 100% Correct, Alex made 5 correct predictions for Petros Pharmaceuticals, Inc. PTPI!

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why is it red HOT?

Petros  reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. 

What did the say, “The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

Alex wrote on Monday 12/13/21 a 5 Day Technical Analysis based on this chart below:

The Predictions

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.” “It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”

Let’s look at each prediction 

Prediction #1  “about to go bearish”

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish “It’s very simple, can it beat $4.38? If it can’t, I would expect a pullback then consolidation and then a run!

Let’s look at where it is around lunch on Wednesday 12/15/21

WOW Alex called prediction 1 with a 38% pullback

Prediction #2 I would expect a pullback then consolidation

“If it can’t, I would expect a pullback then consolidation and then a run!” You can see in the above chart the consolidation call! This is not fortune telling, the chart is like a book and if you know how to read the language it is written in, it makes total sense!

As you can see from the above chart it most definitely consolidated. Let’s see what happened after consolidation!

Alex Goldman Prediction #3: RUN

I would expect a pullback then consolidation and then a run!

As you can see from the above chart it ran MINUTES after the article was finished and gave our subscribers a chance at 28% & 43% RUNS

Alex Goldman Prediction #4: “It is about to run”

Alex wrote a follow up Article HERE Wednesday last week Dated 12/15/21 updating our subscribers

Alex wrote on midday Wednesday 12/15  “It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!”

Alex Goldman Prediction #5: “SCALP”

wait for confirmation of a reversal and get ready for a quick scalp.

Alerted our EXCLUSIVE subscribers via email yesterday 12/20/21.

You can sign up below

Alex wrote in the email on Monday 12/20  “It is now in a bearish trend for the 1 day but still bullish overall. My recommendation is to wait for confirmation of a reversal and get ready for a quick scalp.

SCREENSHOT PROOF FROM OUR EMAIL HERE

OK it is official, Alex really really knows the movement and nuances of this chart! He called yet another massive gain today at 49%

What is Alex’s next prediction for PTPI?

Sign up for our newsletter below, IT’S FREE and you could win $250!

UPDATE: Alex believes Petros Pharma (PTPI) is ready to BOUNCE, PAY ATTENTION!

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

reported positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make 

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

I wrote on Monday 12/13/21 a 5 Day Technical Analysis:

“It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s take a close look at the 1 day.”

Yes, I was right it went BEARISH!

I wrote on Monday 12/13/21 a 1 Day Technical Analysis:

“It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?”

Let’s look at where it is around lunch on Wednesday 12/15/21

WOW I called it, it didn’t break $4.38 and it did PULLBACK 38%! 

Called it AGAIN, Now it is consolidating!

Alex Goldman Prediction:

It is about to run! It is bullish and I like it! Put it on your watchlist and Let’s make some money!!!!

Petros Pharma (PTPI) to launch an OTC Erectile dysfunction pill?

Company Name: Petros Pharmaceuticals, Inc. 

Ticker: (PTPI)

Exchange: NASDAQ

Website: https://STENDRA.com/.

Company Summary:

Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men’s health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men’s health issues, including, but not limited to, erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie’s disease, hormone health, and substance use disorders.

Why did it go up over 100%?

Petros Pharmaceuticals, Inc. (“Petros” or “the Company”) (Nasdaq: PTPI), a leading provider of therapeutics for men’s health, today reports positive over-the-counter (OTC) draft label comprehension study results for its erectile dysfunction (ED) Drug STENDRA® (avanafil). This Pivotal Label Comprehension Study was designed to assess comprehension of a draft STENDRA® Drug Facts Label intended for OTC use. This study is a key component in the Company’s plans to engage in discussions with the FDA to expand the product’s access through application for a possible OTC pathway. Early study indicators show positive label comprehension outcomes in the study, which has encouraged the Company to initiate the next step, a Self-Selection Study, as it continues to build the case for the FDA for OTC access to STENDRA.

“The label comprehension study is a key component of our plans to help expand access for STENDRA beyond the prescription model, and to make STENDRA potentially the first prescription-grade ED medication to become available over-the-counter in the United States. While the process of gathering data to be shared with the U.S. Food and Drug Administration (FDA) continues, we are enthusiastic about our progress toward providing new hope for the millions of men suffering from this condition,” commented Fady Boctor, Petros’s President and Chief Commercial Officer.

The first “potentially the first prescription-grade ED medication to become available over-the-counter in the United States.” EVER?!?

I’m a big fan of this company and the recent news it released. Let’s take a look at the chart.

5 Day Technical Analysis:

It’s been gapping up and pulling back for the last 4 days and it looks like it is still bullish but it is possibly about to go bearish! Let’s tak a close look at the 1 day.

1 Day CHart Technical Analysis

It’s very simple, can it beat $4.38? Yes, then I would wait for a pull back and then swing trade it for a quick scalp. If it can’t, I would expect a pullback then consolidation and then a run! Overall, I love the stock because of the news. The first OTC ED med, say what!?!?

Skip to content